Sherman Morris
Department of Medicine, University of Toronto, ON M5S 1A8, Canada.
Hepat Oncol. 2016 Jan;3(1):13-18. doi: 10.2217/hep.15.35. Epub 2015 Nov 30.
Patients with liver disease have a risk of developing hepatocellular carcinoma (HCC), but the risk varies between different diseases and is also different according to several other variables, such as age, type of underlying liver disease and severity of disease. Several risk scores have been developed to more adequately quantitate HCC risk in individual patients. Each risk score is applicable to a specific population (chronic hepatitis B or C, patients on the transplant list, cirrhosis in general, and so on). Most publications on risk scores do not provide clear guidance as to what level of measured risk is sufficient to trigger surveillance.
肝病患者有发生肝细胞癌(HCC)的风险,但不同疾病的风险有所不同,并且根据其他几个变量(如年龄、潜在肝病类型和疾病严重程度)也存在差异。已经开发了几种风险评分来更充分地量化个体患者的HCC风险。每个风险评分适用于特定人群(慢性乙型或丙型肝炎、移植名单上的患者、一般肝硬化患者等)。大多数关于风险评分的出版物并未就测量的风险达到何种水平足以触发监测提供明确指导。